Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14135197 | 0.82 | MCL1 (0.38) | CYP3A4MAPTNPC1RAB9AMEN1 | |
| SCHEMBL14394902 | 0.79 | CYP3A4 (0.48) | CYP3A4MAPTHTR3EHTR3BHTR3A | |
| SCHEMBL46965 | 0.78 | ALDH1A1 (0.40) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL8042030 | 0.78 | HSD17B10 (0.46) | CYP3A4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5422262 | 0.74 | CYP3A4 (0.48) | CYP3A4MAPTHTR3EHTR3BHTR3A | |
| SCHEMBL13191461 | 0.73 | HDAC1 (0.41) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL14140382 | 0.73 | KMT2A (0.42) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL19523880 | 0.72 | HTT (0.43) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16229877 | 0.70 | CA1 (0.54) | CYP3A4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14273283 | 0.69 | CSNK2A1 (0.51) | CYP3A4MEN1KMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-1865968-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006102604-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217347-A1 | Topical formulations of borinic acid antibiotics and their methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | CYP3A4 3743/4885MAPT 3240/4885HTR3E 4405/4885 |
| US-20060217347-A1 | Topical formulations of borinic acid antibiotics and their methods of use | CUTA, BROX, BTD | CYP3A4 3814/4885MAPT 3761/4885HTR3E 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.